Amgen Beats Earnings Expectations and Expands into Obesity Drug Space

  • 📰 YahooFinanceCA
  • ⏱ Reading Time:
  • 32 sec. here
  • 11 min. at publisher
  • 📊 Quality Score:
  • News: 47%
  • Publisher: 63%

Business News

Amgen,Earnings,Revenue

Amgen reported better-than-expected third-quarter earnings and raised its revenue guidance for the full year. The company recently acquired Horizon Therapeutics, which brings its drug Tepezza to Amgen. Amgen is also venturing into the obesity drug market and has completed enrollment for a phase 2 trial for the treatment of obesity.

) reported third-quarter earnings that beat expectations and raised its full-year revenue guidance. The company recently completed its acquisition of Horizon Therapeutics, which brings its drug Tepezza to Amgen. Amgen is also looking to move into the obesity drug space which has garnered much attention from Wall Street.

Shakedown or smart business? Quebec restaurants balk at hefty penalty for using competitor's payment machines Warren Buffett's Japan trade felt like a gift from God, Charlie Munger says: 'It was awfully easy money' TSX energy stocks such as Suncor Energy should be part of your equity portfolio if you are bullish on oil prices in 2023. The post Oil Prices Are Rising: Here Are the Stocks That Will Benefit the Most appeared first on The Motley Fool Canada.Rated lowest margin fees by StockBrokers.com. Borrow against your securities at low cost. Rates subject to change. Your capital is at risk.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 47. in İE

Ireland Ireland Latest News, Ireland Ireland Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Amgen Reports 5% Rise in Q3 Product Sales After Horizon Therapeutics AcquisitionAmgen announces a 5% increase in third-quarter product sales, driven by double-digit volume growth but offset by lower prices. The company also raises its post-acquisition sales forecast and adjusted earnings outlook for 2023.
Source: SaltWire Network - 🏆 45. / 63 Read more »